Stimulation of osteoblast activity by homocysteine

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 4, 2008, Pages 1205-1210

  Herrmann, Markus ^a   Umanskaya, Natalia ^a   Wildemann, Britt ^b   Colaianni, Graziana ^c   Widmann, Thomas ^a   Zallone, Alberta ^c   Herrmann, Wolfgang ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

Alkaline phosphatase; Cell culture; Homocysteine; Osteoblast; Osteocalcin; Pro collage type I N terminal peptide

Indexed keywords

ACID PHOSPHATASE; HOMOCYSTEINE; OSTEOCALCIN; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N TERMINAL PEPTIDE; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE;

ARTICLE; BONE MATRIX; BONE MINERALIZATION; CELL CULTURE; CYTOLOGY; DRUG EFFECT; HUMAN; METABOLISM; OSTEOBLAST;

ACID PHOSPHATASE; BONE MATRIX; CALCIFICATION, PHYSIOLOGIC; CELLS, CULTURED; HOMOCYSTEINE; HUMANS; OSTEOBLASTS; OSTEOCALCIN; PEPTIDE FRAGMENTS; PROCOLLAGEN;

EID: 49549095609     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00104.x     Document Type: Article

References (32)

1. Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int. 1997 7 : 1 6.
2. Lippuner K, Golder M, Greiner R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int. 2005 2 : S8 17.
3. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002 359 : 1761 7.
4. Melton LJ, III. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res. 2003 18 : 1139 41.
5. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007 22 : 465 75.
6. Kanis JA, Jonsson B. Economic evaluation of interventions for osteoporosis. Osteoporos Int. 2002 13 : 765 7.
7. Walker-Bone K, Walter G, Cooper C. Recent developments in the epidemiology of osteoporosis. Curr Opin Rheumatol. 2002 14 : 411 5.
8. International Osteoporosis Foundation. http://www.iofbonehealth.org/ facts-and-statistics.html#factsheet-category-18. 2007. [accessed on 28 August 2007].
9. Kanis JA, Black D, Cooper C, Dargent P, Dawson- Hughes B, De Laet C, Delmas P, Eisman J, Johnell O, Jonsson B, Melton L, Oden A, Papapoulos S, Pols H, Rizzoli R, Silman A, Tenenhouse A. International Osteoporosis Foundation; National Osteoporosis Foundation. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int. 2002 13 : 527 36.
10. Eisman J, Clapham S, Kehoe L. Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study. J Bone Miner Res. 2004 19 : 1969 75
11. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC Jr., Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR, Anderson RJ, Bergman DA, Bloomgarden ZT, Dickey RA, Palumbo PJ, Peters AL, Rettinger HI, Rodbard HW, Rubenstein HA. AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of post-menopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003 9 : 544 64.
12. Bainbridge KE, Sowers M, Lin X, Harlow SD. Risk factors for low bone mineral density and the 6-year rate of bone loss among premenopausal and perimenopausal women. Osteoporos Int. 2004 15 : 439 46.
13. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, Van Der Klift M, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen J P, Breteler MM, Lips P, Pols HA, Uitterlinden AG. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004 350 : 2033 41.
14. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, Hannan MT, Cupples LA, Kiel DP. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004 350 : 2042 9.
15. Herrmann M, Wildemann B, Claes L, Klohs S, Ohnmacht M, Taban-Shomal O, Hüner U, Pexa A, Umanskaya N, Herrmann W. Experimental hyperhomo- cysteinemia reduces bone quality in rats. Clin Chem. 2007 53 : 1455 61.
16. Herrmann M, Kraenzlin M, Pape G, Sand-Hill M, Herrmann W. Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women. Clin Chem Lab Med. 2005 43 : 1118 23.
17. 12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res. 2005 20 : 921 9.
18. Bode MK, Laitinen P, Risteli J, Uusimaa P, Juvonen T. Atherosclerosis, type 1 collagen cross-linking and homocysteine. Atherosclerosis. 2000 152 : 531 2.
19. Herrmann M, Widmann T, Colaianni G, Colucci S, Zallone A, Herrmann W. Increased osteoclast activity in the presence of increased homocysteine concentrations. Clin Chem. 2005 51 : 2348 53.
20. Koh JM, Lee YS, Kim YS, Kim DJ, Kim HH, Park JY, Lee KU, Kim GS. Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation. J Bone Miner Res. 2006 21 : 1003 11.
21. McKusick VA. Heritable disorders of connective tissue. 1 st ed. St. Louis : Mosby 1966.
22. Herrmann M, Widmann T, Herrmann W. Elevated serum homocysteine and McKusick's hypothesis of a disturbed collagen cross-linking: what do we really know? Bone. 2006 39 : 1385 6.
23. Sakamoto W, Isomura H, Fujie K, Deyama Y, Kato A, Nishihira J, Izumi H. Homocysteine attenuates the expression of osteocalcin but enhances osteopontin in MC3T3-E1 preosteoblastic cells. Biochim Biophys Acta. 2005 1740 : 12 6.
24. Kim DJ, Koh JM, Lee O, Kim NJ, Lee YS, Kim YS, Park JY, Lee KU, Kim GS. Homocysteine enhances apoptosis in human bone marrow stromal cells. Bone. 2006 39 : 582 90.
25. Siggelkow H, Rebenstorff K, Kurre W, Niedhart C, Engel I, Schulz H, Atkinson MJ, Hufner M. Development of the osteoblast phenotype in primary human osteoblasts in culture: comparison with rat calvarial cells in osteoblast differentiation. J Cell Biochem. 1999 75 : 22 35.
26. Stein GS, Lian JB. Molecular mechanisms mediating proliferation/ differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev. 1993 14 : 424 42.
27. wen TA, Aronow M, Shalhoub V, Barone LM, Wilming L, Tassinari MS, Kennedy MB, Pockwinse S, Lian JB, Stein GS. Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J Cell Physiol. 1990 143 : 420 30.
28. Lian JB, Stein GS. Concepts of osteoblast growth and differentiation: basis for modulation of bone cell development and tissue formation. Crit Rev Oral Biol Med. 1992 3 : 269 305.
29. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000 21 : 115 37.
30. Herrmann M, Schmidt J, Umanskaya N, Colaianni G, Al Marrawi F, Widmann T, Zallone A, Wildemann B, Herrmann W. Stimulation of osteoclast activity by low B vitamin concentrations. Bone, In Press, 2007.
31. Saito M, Fujii K, Marumo K. Degree of mineralization-related collagen crosslink-ing in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int. 2006 79 : 160 8.
32. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA. 2005 293 : 1082 8.